Chemomab Therapeutics Ltd ADR (CMMB) Stock Price, Quote & News

Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemi...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 77 331 0156

Website: www.chemomab.com

Address:

Building C, 10th Floor 10 Habarzel Street, Tel Aviv-Yafo, Israel

Snptrader Jul. 16 at 8:15 PM

$CMMB https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=320198403&type=HTML&symbol=CMMB&cdn=749a647f0c32d050410aaae8c9614dd1&companyName=Chemomab+Therapeutics+Ltd.&formType=SCHEDULE+13D&dateFiled=2026-07-16

2 · Reply

DLTT4489 Jul. 16 at 7:17 PM

$CMMB show it to me, you getting close

0 · Reply

W2Cap Jul. 16 at 3:38 PM

$CMMB I agree with this. I hope along with the S4 they take a proactive approach to investor comms. I've suggested to Ryan Phan on LinkedIn that they consider an investor q&a along with a more retail focused Reddit AMA. Likelihood they ignore all of those suggestions; I've only done branding for PLC's for years. Not like I know marketing.

1 · Reply

InvestorNOR Jul. 16 at 3:09 PM

$CMMB I guess its time to stop watching these prices and instead come back in 4 weeks time to read the S-4 and what the combined entity will be like. Im already set with my shares and the merger is the next thing for this stock. Unless they get some PSC Phase 3 partnership/aquirer. Then price should really go up. But I guess merger is most likely short term, in 2.5 months+ from now

0 · Reply

DLTT4489 Jul. 15 at 10:12 PM

$JAGX it's getting close Same will happen to $CMMB Also don't forget another scam company $AIM 🤭🤭😜😜

0 · Reply

InvestorNOR Jul. 15 at 7:07 PM

$CMMB Doubt there are any holders left from 10+ Have to go back to before 2023 to find that price. Most should be ok at $6+

2 · Reply

InvestorNOR Jul. 15 at 5:06 PM

$CMMB From a tiny 22k volume they have managed to get fluctuate SP from 1.63 to 1.52.

0 · Reply

DLTT4489 Jul. 15 at 4:27 PM

$CMMB ready??

0 · Reply

W2Cap Jul. 15 at 10:17 AM

$CMMB My point is that using the technology for Chemomab's programmes does both. Ie, it helps make Chemomab's trials more effective and more likely to succeed - whilst then giving Scipher a massive use case for their technology. If Sciphers PrismRA helps deliver a successful ph2 for a market that hasn't had a drug approved since 2012 (RA), that is then proof of concept for PrismRA. I think it's a ''we have this technology, Chemomab has these programmes, use our tech to get it done, we end up with successful programmes and a successful pilot''.

0 · Reply

Zdxss1 Jul. 15 at 9:30 AM

$CMMB Correct that Scipher benefits from proving the feasibility of PrismRA, but likewise CMMB gains from the merger through asset diversification, risk reduction, and linking itself to the autoimmune sector. • It cannot be said that CMMB tied its fate solely to the RA program, as it has other clinical pipelines that cannot be ignored. • Most importantly, the fate of CMMB shareholders is not limited to PrismRA; there are additional rights through CVR, which is a crucial element that must be emphasized since it defines the future returns for shareholders. • Focusing only on Scipher is a mistake, because CMMB has multiple therapeutic pathways, and any deal or merger must be read primarily from the perspective of protecting shareholder interests.

0 · Reply

Chemomab Therapeutics Transcript: M&A announcement

Jul 8, 2026, 8:30 AM EDT - 8 days ago

Chemomab Therapeutics Press release: M&A announcement

Jul 8, 2026, 8:30 AM EDT - 8 days ago

Chemomab Therapeutics Slides: M&A announcement

2026-07-08T11:46:10.000Z - 8 days ago

Chemomab Therapeutics, Scipher Medicine announce merger agreement

Jul 8, 2026, 7:35 AM EDT - 8 days ago

Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis

May 14, 2026, 8:00 AM EDT - 2 months ago

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026, 8:00 AM EDT - 2 months ago

Chemomab Therapeutics Earnings release: Q1 2026

2026-03-19T12:11:46.000Z - 4 months ago

Chemomab Therapeutics sees cash runway through 1Q27

2026-03-19T12:05:34.000Z - 4 months ago

Chemomab Therapeutics reports FY25 EPS (1c) vs. (4c) last year

Mar 19, 2026, 8:00 AM EDT - 4 months ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

Mar 19, 2026, 8:00 AM EDT - 4 months ago

Chemomab Therapeutics Annual report: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 4 months ago

Chemomab Therapeutics Earnings release: Q4 2025

Mar 1, 2026, 6:00 AM EST - 4 months ago

Chemomab Therapeutics Slides: Corporate presentation

Feb 26, 2026, 8:00 AM EST - 5 months ago

Chemomab Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 17, 2026, 8:00 AM EST - 5 months ago

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

2025-12-02T13:15:59.000Z - 8 months ago

Chemomab Therapeutics announces results of its Phase 2 SPRING trial

Dec 2, 2025, 8:00 AM EST - 8 months ago

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Nov 24, 2025, 8:00 AM EST - 8 months ago

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Nov 21, 2025, 7:00 AM EST - 8 months ago

Chemomab Therapeutics Earnings release: Q3 2025

2025-11-20T13:05:27.000Z - 8 months ago

Chemomab Therapeutics reports Q3 EPS (0.4c) vs (1c) last year

Nov 20, 2025, 8:00 AM EST - 8 months ago

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

2025-11-06T13:47:57.000Z - 9 months ago

Chemomab announces presentations at AASLD 2025 on nebokitug data

Nov 6, 2025, 8:00 AM EST - 9 months ago

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

2025-09-12T16:55:11.000Z - 10 months ago

Chemomab Therapeutics management to meet with Maxim

Sep 5, 2025, 7:00 AM EDT - 11 months ago

Chemomab Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

2025-08-27T16:21:06.000Z - 11 months ago

Chemomab Therapeutics price target raised to $25 from $10 at Oppenheimer

2025-08-25T23:50:06.000Z - 11 months ago

Chemomab Therapeutics Ltd – ADR trading halted, news pending

Aug 21, 2025, 8:00 AM EDT - 11 months ago

Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

2025-08-14T12:11:23.000Z - 1 year ago

Chemomab Therapeutics reports Q2 EPS 0.4c vs 0.013c last year

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 6:00 PM EDT - 1 year ago

Chemomab Therapeutics Earnings release: Q2 2025

2025-07-31T17:55:26.000Z - 1 year ago

Chemomab Therapeutics management to meet with Maxim

2025-06-30T14:35:01.000Z - 1 year ago

Chemomab Therapeutics announces data from Phase 2 SPRING trial of nebokitug

Jun 30, 2025, 8:00 AM EDT - 1 year ago

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25

2025-06-11T12:05:42.000Z - 1 year ago

Chemomab obtained feedback from two recent FDA meetings on nebokitug

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

2025-06-03T12:05:13.000Z - 1 year ago

Chemomab announces nebokitug awarded new patent protection in China, Russia

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

2025-05-16T11:36:15.000Z - 1 year ago

Chemomab Therapeutics price target lowered to $10 from $11 at Oppenheimer

2025-05-15T12:16:43.000Z - 1 year ago

Chemomab Therapeutics reports Q1 EPS $0.007 vs $0.014 last year

May 15, 2025, 8:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025, 8:00 AM EDT - 1 year ago

Chemomab Therapeutics Earnings release: Q1 2025

2025-05-05T12:11:50.000Z - 1 year ago

Chemomab Therapeutics announces presentation of Phase 2 data of CM-101

May 5, 2025, 8:00 AM EDT - 1 year ago

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

2025-04-28T12:31:07.000Z - 1 year ago

Chemomab Therapeutics reports new clinical data at EASL 2025 on nebokitug

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Chemomab Announces New Medical and Clinical Appointments

Mar 27, 2025, 8:30 AM EDT - 1 year ago

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

Mar 6, 2025, 8:00 AM EST - 1 year ago

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis

Mar 3, 2025, 8:00 AM EST - 1 year ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

Mar 3, 2025, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Annual report: Q4 2024

Mar 3, 2025, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Earnings release: Q4 2024

Feb 19, 2025, 7:00 AM EST - 1 year ago

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

Feb 11, 2025, 8:00 AM EST - 1 year ago

Chemomab Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Nov 19, 2024, 7:00 AM EST - 1 year ago

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Nov 14, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Earnings release: Q3 2024

Aug 23, 2024, 8:00 AM EDT - 2 years ago

Chemomab Therapeutics Registration statement: Registration Filing

Aug 21, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 21, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Jul 30, 2024, 9:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Jul 26, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Jul 25, 2024, 8:00 AM EDT - 2 years ago

Chemomab Therapeutics Transcript: Study Result

Jul 25, 2024, 8:00 AM EDT - 2 years ago

Chemomab Therapeutics Press release: Study Result

Jul 25, 2024, 8:00 AM EDT - 2 years ago

Chemomab Therapeutics Slides: Study Result

Jul 25, 2024, 7:38 AM EDT - 2 years ago

Chemomab Therapeutics Announces $10 Million Private Placement

Jul 25, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Jun 6, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

May 17, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

May 9, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

May 2, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

Apr 24, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

Apr 18, 2024, 7:00 AM EDT - 2 years ago

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Apr 10, 2024, 10:00 AM EDT - 2 years ago

Chemomab Therapeutics Transcript: KOL Event

Apr 2, 2024, 7:00 AM EDT - 2 years ago

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Mar 25, 2024, 7:06 AM EDT - 2 years ago

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Mar 7, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

Mar 7, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Annual report: Q4 2023

Mar 7, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Earnings release: Q4 2023

Mar 5, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

Feb 20, 2024, 7:00 AM EST - 2 years ago

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Feb 14, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Feb 5, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

Jan 30, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Jan 3, 2024, 7:00 AM EST - 2 years ago

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024

Nov 16, 2023, 7:00 AM EST - 2 years ago

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

Nov 15, 2023, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

Nov 13, 2023, 8:00 AM EST - 2 years ago

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023

Nov 9, 2023, 8:00 AM EST - 2 years ago

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Earnings release: Q3 2023

Nov 6, 2023, 4:15 PM EST - 2 years ago

Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Snptrader Jul. 16 at 8:15 PM

2 · Reply

DLTT4489 Jul. 16 at 7:17 PM

$CMMB show it to me, you getting close

0 · Reply

W2Cap Jul. 16 at 3:38 PM

1 · Reply

InvestorNOR Jul. 16 at 3:09 PM

0 · Reply

DLTT4489 Jul. 15 at 10:12 PM

$JAGX it's getting close Same will happen to $CMMB Also don't forget another scam company $AIM 🤭🤭😜😜

0 · Reply

InvestorNOR Jul. 15 at 7:07 PM

$CMMB Doubt there are any holders left from 10+ Have to go back to before 2023 to find that price. Most should be ok at $6+

2 · Reply

InvestorNOR Jul. 15 at 5:06 PM

$CMMB From a tiny 22k volume they have managed to get fluctuate SP from 1.63 to 1.52.

0 · Reply

DLTT4489 Jul. 15 at 4:27 PM

$CMMB ready??

0 · Reply

W2Cap Jul. 15 at 10:17 AM

0 · Reply

Zdxss1 Jul. 15 at 9:30 AM

0 · Reply

W2Cap Jul. 15 at 8:25 AM

$CMMB Given the reported struggles of PrismRA (court case, $10M run rate)... I'm starting to wonder if the company's plan is to use PrismRA successfully for this RA programme, solely to prove concept that it works and be able to then grow it. Think about it - they're going to all these BP pushing their molecular testing, struggling to get it off the ground. So they buy a company in the auto-immune disease space - use the test to successfully get past PH2... They make money from the success, but also get the exposure and credibility.

0 · Reply

W2Cap Jul. 15 at 8:22 AM

$CMMB This is easier said than done. As an owner of the stock at $1.92 average (I averaged up on the run, frustratingly); a $75M deal would be a great return for me. But is that a great return for early investors that have been here for years? no. Not at all. is the 10% holder who invested hundreds of millions going to go ''yeah ok'' on that? no. I guess the RA element is that if a phase 2 RA is ever approved it would be a multi billion dollar a year drug and the kind of returns from their IPO would be realised. And for a lot of those investors a 5-6 maybe even 7 year wait for that is totally cool with them.

0 · Reply

Zdxss1 Jul. 15 at 2:38 AM

$CMMB CMMB shareholders are torn between worry and fear caused by the stock’s decline, and the company’s exceptional scientific and regulatory value with optimistic future prospects. Managing the fear, stress, and anxiety triggered by the drop in the stock price calls for patience and control over our emotions and concerns

0 · Reply

Stockhunter008 Jul. 14 at 9:42 PM

$CMMB any way you look at it, $CMMB is now effectively trading at cash levels assuming the $30 million PIPE. With CMMB owning 32% of it. Kinda crazy. Basically, the Nebokitug asset and the SCIFER business are being valued at zero.

0 · Reply

InvestorNOR Jul. 14 at 9:03 PM

$CMMB Higher market cap also typically come from dilution and offerings which these pennystock biotech often does. That they instead go for merger is good news for shareholders I tell you

1 · Reply

Snptrader Jul. 14 at 9:03 PM

$CMMB If I were preparing a fairness opinion or strategic alternatives analysis, the transaction that would draw my attention is Promedior. Roche paid up to $1.4 billion for a company built around a Phase 2 anti-fibrotic platform. By comparison, Chemomab has a Phase 3-ready PSC program, a Phase 2 SSc program, and now an RA strategy tied to precision medicine. Those differences do not prove Chemomab would command a higher valuation in a sale process, but they do suggest that historical fibrosis transactions provide meaningful context for evaluating whether the company's strategic alternatives have been fully explored.

1 · Reply

InvestorNOR Jul. 14 at 8:24 PM

$CMMB How do you propose they sell the company if there are maybe no bidders that have shown interest? Its easy to say "maximize shareholders value" but its not easy for a company that doesnt have revenue either. CRVs and keeping Phase 3 PSC for CMMB shareholders is "maximizing value" in my eyes...

2 · Reply

DLTT4489 Jul. 14 at 8:00 PM

$CMMB show me $$1.31 by friday

0 · Reply

DLTT4489 Jul. 14 at 7:58 PM

$CMMB RS, RS, RS. RS, RS, IS IMMINENT. SEAT BACK AND KEEP WATCHING

1 · Reply

DLTT4489 Jul. 14 at 7:56 PM

$CMMB what do you expect dude?? $4-5?? You'll see 0.40-0.50 soon

0 · Reply

DLTT4489 Jul. 14 at 7:55 PM

$CMMB getting close 🤣🤣🤣

0 · Reply

Snptrader Jul. 14 at 6:10 PM

$CMMB Part 1 Since announcing the proposed merger, Chemomab's market cap has fallen to roughly $11M, implying a combined company value of less than $50M. Shareholders have funded approximately $115M to advance nebokitug through years of development, including a Phase 3-ready PSC program, a systemic sclerosis program, and now an AI-guided rheumatoid arthritis opportunity. While past investment alone doesn't determine value, today's market valuation raises serious questions. Before asking shareholders to approve this transaction, the Board should demonstrate that every reasonable alternative has been explored to maximize shareholder value.

1 · Reply

Market Cap	11.02M
Revenue (ttm)	0.00
Net Income (ttm)	-9.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	105,100
Avg Vol	142,986
Day's Range	N/A - N/A
Shares Out	7.20M
Stochastic %K	2%
Beta	0.64
Analysts	Sell
Price Target	$5.00